<--- Back to Details
First PageDocument Content
Neutron facilities / Australian Nuclear Science and Technology Organisation / Nuclear energy in Australia / Nuclear power in Australia / High Flux Australian Reactor / Ann Henderson-Sellers / Radioligand / Positron emission tomography / Epidermal growth factor receptor / Nuclear technology / Medicine / Nuclear physics
Date: 2010-09-30 20:15:47
Neutron facilities
Australian Nuclear Science and Technology Organisation
Nuclear energy in Australia
Nuclear power in Australia
High Flux Australian Reactor
Ann Henderson-Sellers
Radioligand
Positron emission tomography
Epidermal growth factor receptor
Nuclear technology
Medicine
Nuclear physics

Section 1 Contents President’s Report 2

Add to Reading List

Source URL: www.ainse.edu.au

Download Document from Source Website

File Size: 1,27 MB

Share Document on Facebook

Similar Documents

AbstractProspective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC

DocID: 1rVAJ - View Document

UNIVERSITÄTSKLINIKUM Schleswig-Holstein Immuntherapie des Glioblastoms Sampson et al. - Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor

DocID: 1rgeq - View Document

Tyrosine kinase receptors / Peptidase / Clinical medicine / Cancer / Medicine / Oncogenes / Tyrosine kinases / HER2/neu / Cathepsin B / Epidermal growth factor receptor / ErbB / Cathepsin Z

Abstract ErbB2 overexpression gives rise to a highly invasive, aggressive phenotype associated with an enlarged lysosomal compartment and increased activity of the lysosomal proteases, cysteine cathepsins. We have recent

DocID: 1rdcC - View Document

Tyrosine kinase receptors / Statistics / Cluster analysis / Data analysis / Computational statistics / Hierarchical clustering / Network analysis / Anaplastic lymphoma kinase / K-means clustering / Tyrosine kinase / Dendrogram / Epidermal growth factor receptor

Wrangling Phosphoproteomic Data to Elucidate Cancer Signaling Pathways Mark L. Grimes1*, Wan-Jui Lee2, Laurens van der Maaten2, Paul Shannon3 1 Division of Biological Sciences, University of Montana, Missoula, Montana, U

DocID: 1qMPs - View Document

Lung cancer / Clinical medicine / Cancer / Tyrosine kinase inhibitors / Boehringer Ingelheim / Health / T790M / Protein kinase inhibitor / Epidermal growth factor receptor / Non-small-cell lung carcinoma / Targeted therapy

ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced

DocID: 1qm1i - View Document